Tools
ToolsRakisheva, Amina, Farmakis, Dimitrios, Attanasio, Andrea, Genis, Antoni Bayes, Cohen-Solal, Alain, Gulati, Geeta, Halle, Martin, Hill, Loreena, Fernandez, Teresa Lopez, Lyon, Alexander R., Moura, Brenda, Santoro, Ciro, Tocchetti, Carlo Gabriele, van Linthout, Sophie, Vassiliou, Vassilios, Sener, Yusuf Ziya, Bekbosynova, Makhabbat, Metra, Marco, Rosano, Giuseppe and Piepoli, Massimo (2025) Prevention of cancer therapy-related cardiac dysfunction and heart failure in cancer patients and survivors. A Clinical Consensus Statement of the Heart Failure Association, the European Association of Preventive Cardiology of the ESC, and the ESC Council of Cardio-Oncology. European Journal of Heart Failure, 27 (11). pp. 2084-2099. ISSN 1388-9842
Full text not available from this repository. (Request a copy)Abstract
Despite advances in cancer treatments with significant improvement in patient outcomes, chemotherapy, targeted molecular therapies and radiotherapy may cause a range of cardiovascular complications, such as cancer therapy-related cardiac dysfunction (CTRCD), which represents a broad spectrum of possible presentation and aetiological link with the broad scope of various cancer therapies, including chemotherapy, targeted agents, immunotherapies, and radiation therapy, aiming at reducing the associated morbidity and mortality. However, practical guidelines on the primary prevention of CTRCD in high-risk patients, a key element in improving prognosis, are lacking in cancer patients and related evidence remains inconclusive. This Clinical Consensus Statement, authored by experts from the Heart Failure Association (HFA) and the European Association of Preventive Cardiology (EAPC) of the European Society of Cardiology (ESC), and the ESC Council of Cardio-Oncology, aims to discuss the definition and epidemiology of CTRCD, the implicated factors for risk stratification, and the appropriate early diagnostic pathways, while focusing on lifestyle modifications, and pharmacological interventions to reduce the incidence of CTRCD. In addition, a holistic cardio-oncology management approach is advised for prevention and long-term management.
| Item Type: | Article |
|---|---|
| Additional Information: | Publisher Copyright: © 2025 European Society of Cardiology. |
| Uncontrolled Keywords: | cancer patients and survivors,cancer therapy-related cardiac dysfunction,heart failure prevention,cardiology and cardiovascular medicine,sdg 3 - good health and well-being ,/dk/atira/pure/subjectarea/asjc/2700/2705 |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| UEA Research Groups: | Faculty of Science > Research Groups > Norwich Epidemiology Centre Faculty of Medicine and Health Sciences > Research Groups > Norwich Epidemiology Centre Faculty of Medicine and Health Sciences > Research Groups > Cardiovascular and Metabolic Health Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 03 Mar 2026 15:30 |
| Last Modified: | 03 Mar 2026 15:30 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/102150 |
| DOI: | 10.1002/ejhf.3753 |
Actions (login required)
 |
View Item |